Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial - Cascone, T; Kar, G; Spicer, JD (Cancer Discov, 2023)
et al.